Theseus Pharmaceuticals, Inc.
theseusrx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 17, 2023. Its latest SEC filing is a 15-12G from Feb 26, 2024.
10-Q for Q3 FY2023, filed Nov 17, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops targeted cancer drug candidates for patients with gastrointestinal stromal tumors, lung cancer resistant to targeted drugs, and certain blood cancers.
10-K for FY2022, filed Mar 9, 2023We are a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and…View ↗
Our most advanced product candidate, THE-630, is a pan-variant inhibitor of all major classes of activating and resistance mutations of the…View ↗
Our second product candidate is THE-349, a fourth-generation EGFR inhibitor for the treatment of NSCLC. THE-349 is designed to address…View ↗
Our third program is a next-generation BCR-ABL TKI that we are designing to be potent, selective, and pan-variant—features that we believe…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2022, filed Mar 9, 2023
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 18, 2023
−$13.5MView ↗
- ▼ −8% (Loss)
- vs −$14.7M in Q3 FY2022
-
Feb 14, 2024
Concentra completed its acquisition of Theseus
Theseus became a wholly owned subsidiary of Concentra.
Sources
8-K, filed Feb 14, 2024
Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied, and on…View ↗
-
Dec 4, 2023
The CEO departed as part of a workforce reduction
He also resigned from the board.
Sources
8-K, filed Dec 4, 2023
As part of a reduction in workforce, Theseus Pharmaceuticals, Inc. (the “Company”) terminated the employment of Timothy P. Clackson, Ph.D.…View ↗
-
Oct 31, 2023
Theseus terminated the ARIAD license agreement
The termination followed the decision to stop developing THE-630 for GIST.
Sources
8-K, filed Oct 31, 2023
The Company previously announced in July 2023 that it was discontinuing enrollment in the ongoing Phase 1/2 study and terminating…View ↗
-
Jul 13, 2023
Theseus ended THE-630 development for GIST
The company cited dose-limiting skin reactions at the tested dose.
Sources
8-K, filed Jul 13, 2023
Cambridge, Mass., July 13, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage…View ↗
Who Did They Compete With?
Competes with Blueprint, Cogent, Novartis, Pfizer, Deciphera Pharmaceuticals, Bayer, AB Sciences, Arog Pharmaceuticals, CTTP, Exelixis, IDRX, Immunicum, Jiangsu HengRui, Ningbo Tai Kang Medical Technology, Taiho Pharmaceutical, Xencor, Merck, AstraZeneca, Yuhan, and Jiangsu Hansoh Pharmaceutical Group
10-K for FY2022, filed Mar 9, 2023With respect to our most advanced product candidate, THE-630, there are several large pharmaceutical companies and biotechnology companies…View ↗
Loading...
